Single-Dose PK Study of GBT440 in Subjects With Renal Impairment
Status:
Completed
Trial end date:
2017-07-06
Target enrollment:
Participant gender:
Summary
A Phase 1, multiple center, nonrandomized, open-label, parallel group study of a single oral
dose of GBT440 administered in subjects with mild, moderate, or severe renal impairment
disease and healthy subjects with normal renal function.